This randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the safety and efficacy of two-weeks of nightly sublingual cannabinoid extract (ZTL-101) in treating chronic insomnia (symptoms ≥three months).
The post Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians appeared first on Society of Cannabis Clinicians.